Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

By J. Gisbert, J. Panés. American Journal of Gastroenterology, 2009

716 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/68abfe80860c0b4d9006866050cdbc4ec812e21a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. J. Colombel
2. P. Rutgeerts
3. Markus F. Neurath

In Rheumatology

1. J. Colombel

Citations in the corpus

• Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. (2015, background): “Despite its proven efficacy, up to 60% of patients with an initial response later experience secondary loss of response requiring dose escalation or a switch to another TNF antagonist to recapture response.(4,5) Loss of clinical benefit can be due to increased clearance of the drug in the presence o”
• Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management (2016, background): “1% per patient-year and LOR of 46% to ADA by 54 weeks.(15) In fistulizing CD, LOR at week 54 defined as recurrence of actively draining fistulas was 64%.”